This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain
by Sweta Killa
The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.
Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Biotech ETF (BBC) Hits a New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Uptick in Consumer Confidence Puts 3 Stocks on Top
by Zacks Equity Research
Consumer Confidence rose for the first time since February, reflecting Americans' optimism as the economy reopens.
Dow Touches 25,000 in More Than 2 Months: 4 Blue-Chip Picks
by Nalak Das
The blue-chip index's northbound journey began on Mar 24 and is continuing barring occasional fluctuations.
Here's How Americans Are Regaining Confidence: 5 Picks
by Sanghamitra Saha
U.S. consumer confidence gained in May and beat the expectations of economists polled by Dow Jones.
Pre-Markets Race Higher on Vaccine Hopes
by Mark Vickery
Chief among positives for the market is a new vaccine candidate for COVID-19 from Novavax (NVAX), which is launching its human trials in Australia.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
Coronavirus Vaccine Efforts Continue, Novavax Begins Human Trial
by Kinjel Shah
As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.
Novavax Begins Clinical Study for Coronavirus Vaccine
by Zacks.com
Novavax (NVAX) enrolls the first set of participants in a phase I/II clinical study for evaluating its coronavirus vaccine candidate, NVX-CoV2373.
2 Top Factors Buoy Wall Street Since Memorial Day: 5 Picks
by Tirthankar Chakraborty
As optimism surrounding a coronavirus vaccine and consumer activity begin to pick up, Wall Street is expected to trade higher.
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
by Sanghamitra Saha
Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.
Coronavirus Vaccine Development Gathers Steam: 4 Winners
by Ritujay Ghosh
Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.
S&P Set to Open Above 3000
by Jeremy Mullin
Bulls start the week trying to break the 200-day moving average.
Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain
by Sweta Jaiswal, FRM
Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.
Wining ETF Areas of Last Week
by Sanghamitra Saha
Though last week was not upbeat for Wall Street, these ETFs breezed past Wall Street.
Leveraged ETFs of Last Week
by Sanghamitra Saha
These leveraged ETFs were outperformers last week.
Is Novavax (NVAX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
Novovax (NVAX) Surges on CEPI Funding for Coronavirus Vaccine
by Zacks Equity Research
Novovax (NVAX) is set to receive funding of up to $388 million from CEPI to support clinical development and scaling up of production of its coronavirus vaccine candidate.
Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain
by Sweta Jaiswal, FRM
Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.
Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of 13.43% and -3.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Novavax (NVAX)
by Zacks Equity Research
Novavax (NVAX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Emergent (EBS) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Emergent's (EBS) earnings and revenues surpass estimates in the first quarter of 2020. The company reaffirms its guidance for the ongoing year.
Novavax (NVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $18.13 in the latest trading session, marking a -1.52% move from the prior day.
Novavax (NVAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.